Investing.com - Evotec SE ADR reported on Wednesday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations. Evotec SE ADR announced ...
Discover Evotec SE's groundbreaking patent for ENaC-inhibiting compounds, offering innovative treatments for respiratory, skin, and ocular diseases. Explore their potential!